The FY2025 (Dec) proxy of Immunocore Holdings names 20 peer companies for pay. Among Immunocore Holdings and these peers, CEO pay was 4th highest of 7 and total shareholder return was 4th highest of 7.
4th highest of 7in Immunocore Holdings and its pay peers, FY2025 (Dec) by CEO pay:
$5.8M$25.6M
4th highest of 7in Immunocore Holdings and its pay peers, FY2025 (Dec) by total shareholder return:
$23$247
Pay peer group, FY2025 (Dec) proxy
| TG Therapeutics | ||
| Revolution Medicines | ||
| Ionis Pharmaceuticals | ||
| IDEAYA Biosciences | ||
| Vir Biotechnology | ||
| Beam Therapeutics | ||
| Amicus Therapeutics | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals | Not disclosed | Not disclosed |
| Arcus Biosciences | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Arvinas | Not disclosed | Not disclosed |
| Axsome Therapeutics | Not disclosed | Not disclosed |
| Bicycle Therapeutics | Not disclosed | Not disclosed |
| Blueprint Medicines | Not disclosed | Not disclosed |
| Galapagos NV | Not disclosed | Not disclosed |
| Immatics | Not disclosed | Not disclosed |
| Intra-Cellular Therapies | Not disclosed | Not disclosed |
| Legend Biotech | Not disclosed | Not disclosed |
| Mirium Pharmaceuticals | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
20 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.